Io Therapeutics Inc. has presented new preclinical data on their RARγ agonist IRX-5010 for the treatment of triple-negative ...

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

can counteract resistance to anti-PD-1 and anti-PD-L1 therapies in solid tumors. Cancer immunotherapies targeting immune checkpoint molecules have revolutionized treatment across various cancer ...

JSKN033-102 is an open-label, multicenter, Phase Ⅰ/Ⅱ clinical study designed to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and anti-tumor activity of JSKN033 in patients with ...

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches ...

I-Mab, a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment ...

FDA 授予 LBL-024 孤儿药资格认定，LBL-024 是一种抗 PD-L1/4-1BB ...

ROCKVILLE, MD, USA I January 6, 2025 I I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...